## GSK2983559

®

MedChemExpress

Cat. No.:	HY-112038A	S
Molecular Formula:	$C_{21}H_{28}CaN_{4}O_{10}PS_{2}^{+}$	N N
Molecular Weight:	612	O HN
Target:	RIP kinase	S O O
Pathway:	Apoptosis	
Storage:	-20°C, sealed storage, away from moisture * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)	$H^{O}$ $H^{O$

SOLVENT & SOLUBILITY	

In Vitro	DMSO : < 1 mg/mL (ultrasonic;warming;heat to 80°C) (insoluble or slightly soluble)
	DMF : < 1 mg/mL (ultrasonic;warming;heat to 80°C) (insoluble)
	Ethanol : < 1 mg/mL (ultrasonic) (insoluble)

BIOLOGICAL ACTIVITY					
Description	GSK2983559 is an orally active and potent receptor interacting protein 2 (RIP2) kinase inhibitor. GSK2983559 blocks many proinflammatory cytokine responses in vivo and in human inflammatory bowel disease explant samples <sup>[1]</sup> .				
IC <sub>50</sub> & Target	RIPK2				
In Vitro	GSK2983559 (1-1024 nM; 2 h) blocks MDP-induced IL-8 in THP-1 cells <sup>[2]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Viability Assay <sup>[2]</sup>				
	Cell Line:	THP-1 cells			
	Concentration:	1-1024 nM			
	Incubation Time:	2 hours			
	Result:	Inhibited IL-8 production with an IC <sub>50</sub> of 1.34 nM.			
In Vivo	GSK2983559 (oral gavage; 3 and 10 mg/kg; once) inhibits effectively MDP-induced IL-6 in mouse <sup>[2]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.				
	Animal Model:	C57BL/6 mice (female) injected with MDP (100 $\mu g)^{[2]}$			
	Dosage:	3 and 10 mg/kg			
	Administration:	Oral gavage; 3 and 10 mg/kg; once			

## Product Data Sheet

Result:

## REFERENCES

[1]. Pamela A Haile, et al. Discovery of a First-in-Class Receptor Interacting Protein 2 (RIP2) Kinase Specific Clinical Candidate, 2-((4-(Benzo[d]thiazol-5-ylamino)-6-(tertbutylsulfonyl)quinazolin-7-yl)oxy)ethyl Dihydrogen Phosphate, for the Treatment of Inflammatory Diseases. J Med Chem. 2019 Jul 25;62(14):6482-6494.

[2]. Shuwei Wu, et al. Design, synthesis, and structure-activity relationship of novel RIPK2 inhibitors. Bioorg Med Chem Lett. 2022 Sep 2;75:128968.

## Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA